Implantica Collaborates with La Paz University Hospital
Implantica AG is making waves in the medical technology realm with its latest collaboration. The company has established a partnership with La Paz University Hospital, one of the top hospitals in Spain, to implement innovative treatments for gastroesophageal reflux disease (GERD). This partnership marks a significant milestone as La Paz Hospital becomes the 12th Center of Excellence for the pioneering RefluxStop™ procedure.
Advancing GERD Treatment at La Paz University Hospital
Under the leadership of Dr. Pablo Priego, the Chief of the Esophagogastric and Bariatric Surgical Unit, La Paz University Hospital has already successfully carried out the first two procedures using RefluxStop™. The hospital is not only known for its high standards in quality of care but also as a teaching institution with a strong emphasis on research and innovation in the field of surgery.
What Makes RefluxStop™ Unique?
RefluxStop™ stands out from traditional anti-reflux surgeries, which typically encircle the food passageway. This new method aims to treat GERD without applying pressure on the esophagus, thus minimizing the risk of common side effects like swallowing difficulties. Patients previously deemed unsuitable for traditional surgical options can now benefit from this forward-thinking solution.
Impacts on Patients Suffering from GERD
Approximately 15% of the adult population experiences symptoms of GERD, leaving many to struggle with unresolved issues stemming from inadequate treatment options. Dr. Peter Forsell, the inventor of RefluxStop™ and CEO of Implantica, expressed profound gratitude towards La Paz Hospital’s commitment to addressing the needs of these patients by implementing this transformative technology.
Commitment to Innovation and Patient Care
Implantica is dedicated to revolutionizing the treatment landscape for acid reflux sufferers. Dr. Forsell highlighted the importance of collaboration with leading health institutions to enhance patient care and provide cutting-edge solutions. The partnership with La Paz University Hospital signifies a forward leap in delivering effective treatments for individuals enduring chronic acid reflux.
About Implantica
Implantica is a trailblazer in medtech, focusing on integrating advanced technology into medical solutions. Their flagship product, RefluxStop™, is a CE-marked implant that has shown promising results in clinical trials aimed at preventing gastroesophageal reflux. The company is also at the forefront of developing eHealth solutions that monitor health parameters and enhance patient care from within the body.
The Future of Anti-Reflux Treatment
The RefluxStop™ device is designed with a unique mechanism that supports the body's anatomy without applying pressure or obstructing the esophagus. It addresses the fundamental causes of acid reflux by restoring the natural physiology of the lower esophageal sphincter, thereby fostering a sustainable solution for patients who have endured GERD symptoms for years.
Frequently Asked Questions
What is RefluxStop™?
RefluxStop™ is an innovative implant designed to prevent gastroesophageal reflux disease (GERD) without encircling the food passageway, minimizing side effects.
What role does La Paz University Hospital play in this partnership?
La Paz University Hospital acts as a Center of Excellence, implementing RefluxStop™ procedures to provide advanced care for GERD patients.
Why is this partnership important for GERD treatment?
This partnership enhances access to innovative treatment methods for GERD, addressing significant unmet medical needs among patients.
Who are the key figures associated with RefluxStop™?
Dr. Pablo Priego and Dr. Peter Forsell are pivotal in advocating for the RefluxStop™ procedure and its implementation at La Paz University Hospital.
How can patients access RefluxStop™?
Patients should consult their healthcare providers to explore the possibility of receiving RefluxStop™ treatment at accredited facilities like La Paz University Hospital.
